Discussing Seladelpar as a Potential Therapeutic for PBC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

Now Viewing

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

Video content above is prompted by the following:

Seladelpar has been studied extensively, with the RESPONSE trial serving as one of its landmark studies. What are the key efficacy findings from this trial?